IP Library Granted Patent US 10,172,707
Granted Patent B2
US 10,172,707 · App. 14/351,408 · Granted Jan 8, 2019

Tubular prostheses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,172,707
App. No.
14/351,408
Granted
Jan 8, 2019
Kind
B2
Abstract

Tubular prostheses are provided for use in airways, upper digestive, and urinary tracts. Each of these uses has its own specific sets of biological specifications, based on what it must contain and exclude and the physical and chemical pressures and stresses to which it is subjected. The prostheses may be made from allogeneic cells. Thus they can be manufactured and stored prior to an individual's personal need arising.

Claims (12)

1. An artificial stented urinary conduit for implantation in a patient in need of urinary diversion and drainage, comprising:

a tubular, substantially acellular, extracellular matrix formed as a tube on a biodegradable scaffold, wherein the extracellular matrix was produced and secreted in vitro by non-autologous smooth muscle cells grown around a tubular, non-degradable stent such that the extracellular matrix totally envelopes and encases the stent on its inner and outer surfaces, wherein the extracellular matrix is rotationally fixed with respect to the stent.

2. The artificial urinary conduit of claim 1 wherein the tubular stent comprises metal.

3. The artificial urinary conduit of claim 1 wherein the tubular stent comprises a polymer.

4. The artificial urinary conduit of claim 1 wherein the tubular stent is perforated.

5. The artificial urinary conduit of claim 1 wherein the extracellular matrix forms a tubular tissue that is not subject to deconvolution.

6. The artificial urinary conduit of claim 1 wherein the artificial stented urinary conduit is manufactured using banked cells.

7. The artificial urinary conduit of claim 1 wherein the artificial stented urinary conduit is pre-manufactured prior to implantation.

8. The artificial urinary conduit of claim 1 wherein collagen comprises at least 20% of the extracellular matrix.

9. The artificial urinary conduit of claim 1 wherein collagen comprises at least 25% of the extracellular matrix.

10. The artificial urinary conduit of claim 1 wherein collagen comprises at least 30% of the extracellular matrix.

11. The artificial urinary conduit of claim 1 wherein the artificial urinary conduit has a rupture strength of greater than 1000 mm Hg and up to 2000 mm Hg.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Dec 16, 2025
From: HOOK SA LLC, AS PURCHASER AGENT
To: HUMACYTE GLOBAL, INC.
Reel/Frame 073234/0064 →
SECURITY INTEREST Recorded Dec 15, 2025
From: HUMACYTE, INC.; HUMACYTE GLOBAL, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND II, L.P., AS AGENT
Reel/Frame 073214/0250 →
SECURITY INTEREST Recorded May 15, 2023
From: HUMACYTE GLOBAL, INC.
To: HOOK SA LLC, AS PURCHASER AGENT
Reel/Frame 063638/0933 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2016
From: NIKLASON, LAURA
To: HUMACYTE, INC.; YALE UNIVERSITY
Reel/Frame 040431/0671 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2016
From: HUANG, ANGEL; ZHAO, LIPING
To: YALE UNIVERSITY
Reel/Frame 040431/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2016
From: DAHL, SHANNON
To: HUMACYTE, INC.
Reel/Frame 040431/0710 →